Bilcare Global Clinical Supplies (GCS), a leading single-source provider of clinical trial services, has formed its first corporate advisory board with Dr John LaMattina, former president of Pfizer and Dr Arthur Carty, executive director of Waterloo Institute of Nanotechnology, as its members. Dr. LaMattina will serve as chairman of the board.

"The formation of our corporate advisory board is another major milestone in our mission to make Bilcare GCS a global leader in the clinical trial supplies arena. The addition of these accomplished members will prove to be a tremendous asset to research and innovation initiatives of our company," said, Mohan Bhandari, chairman and managing director, Bilcare Limited.

The advisory board is created to provide Bilcare GCS management team with independent scientific industry expertise and insight to assist in the accomplishment of scientific and business objectives.

"I am honoured to be on the corporate advisory board of a company that is on the rise and gaining well-deserved recognition throughout the industry. I am confident that the advisory board will play a pivotal role in the future success of Bilcare's contribution to the Clinical Research Industry," said, LaMattina.

Referring to his duties as a member of advisory board, Arthur Carty said, "Serving on the corporate Advisory Board is an honour and comes with great responsibility. I am committed to provide technology and biotech expertise to Bilcare GCS to further its business objectives."

Bilcare Global Clinical Supplies serves the Americas, Europe and Asia with clinical trial materials support, services and complete project management. The company's services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical trial materials (CTM) satisfy a broad range of requirements, from pre-formulation research and development, analytical services and clinical supplies packaging and labelling, to IVRS and controlled temperature (cold and frozen chain) CTM storage.

"We are honoured to have Dr LaMattina and Dr Carty as an integral part of the Bilcare team and look forward to a long association with them and to their successful contribution especially in the areas of technology, research and innovation," said, Vito Mangiardi, CEO, GCS Bilcare.